Abiomed receives fda pma approval for impella 5.5 with smartassist

Abiomed receives fda pma approval for impella 5.5 with smartassist, a minimally invasive, forward flow heart pump.abiomed receives fda pma approval for impella 5.5 with smartassist, a minimally invasive, forward flow heart pump.abiomed - impella 5.5 has received u.s. fda pre-market approval for safety & efficacy in therapy of cardiogenic shock for up to 14 days.
ABMD Ratings Summary
ABMD Quant Ranking